|
- Chinese pharma is on the cusp of going global - The Economist
Chinese pharma is on the cusp of going global Its fast-moving, cut-price drugmakers stand to make more money abroad than at home
- Chinese pharma is on the cusp of going global (Economist)
Its fast-moving, cut-price drugmakers stand to make more money abroad than at home After america, China is the world’s largest developer of new medicines and its companies ran about a third of the planet’s clinical trials last year That is up from just 5% a decade before (see chart 1) It is also rising to the forefront in critical areas of research, such as those relating to cancer
- Chinese pharma is on the cusp of going global| Business News
For Chinese drugmakers, the real test is not only inventing novel therapies that work but breaking into new markets and passing the regulatory hurdles associated with them
- Chinese Pharma is On the Cusp of Going Global - Pipedot
In the first half of 2025, nearly a third of global licensing agreements signed by big pharma involved Chinese firms, Economist reports, four times the share from 2021 Pfizer agreed in May to pay $1 25 billion to 3SBio for an experimental cancer drug, and GlaxoSmithKline followed in June with a deal valued at up to $12 billion with Hengrui
- Chinese Pharma is On the Cusp of Going Global - Slashdot
Chinese Pharma is On the Cusp of Going Global (economist com) 47 Posted by msmash on Wednesday November 26, 2025 @05:41PM from the PSA dept
- MAESTrO: Chinese pharma is on the cusp of going global
After Amecica, China is the world's largest developer of new medicines and its companies ran about a third of the planet's clinical trials last year That is up from just 5% a decade before It is also rising to the forefront in critical areas of research, such as those relating to cancer Investors have taken note Shares in Chinese biotech companies have surged by 110% this year, more than
- Chinese-made new drugs big hit overseas - Chinadaily. com. cn
The US accounted for over half of global innovative drug sales in 2021, with Europe at 16 percent, while China stood at merely 3 percent, far below that of developed countries, according to a report by consultancy Market Monitor
|
|
|